Takutsubo-associated cardiogenic shock has lower mortality and hospital costs..... Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial ... https://t.co/tGQ7GpLA7c
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @JACCJournals: How does cardiogenic shock behave in #Takotsubo cardiomyopathy compared to #cvAMI? Findings from the largest study on car…
RT @JACCJournals: How does cardiogenic shock behave in #Takotsubo cardiomyopathy compared to #cvAMI? Findings from the largest study on car…
RT @JACCJournals: How does cardiogenic shock behave in #Takotsubo cardiomyopathy compared to #cvAMI? Findings from the largest study on car…
How does cardiogenic shock behave in #Takotsubo cardiomyopathy compared to #cvAMI? Findings from the largest study on cardiogenic shock in Takotsubo are now available in #JACCHF. https://t.co/7hU93hZ6IH https://t.co/vcpFidU7QP
Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction https://t.co/ZWP4ExAWmo
A,K key Their concept is killing everyone I have ever known & anyone who might protest & then make a show of mutilating, raping & killing me as a sort of complete victory over NN hetero for FBI/Pentagon super predator assholes.
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction https://t.co/S8sYfdKAuG
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
Excellent and much needed study @SarasVallabhMD
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
RT @krychtiukmd: Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteri…
Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction - key differences in clincial characteristics and organ failure shown in a huge CS database! #Cardiology #Cardiotwitter #cardshock #shock #ESCACCA https://t.co/e7Tt770aVc
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
RT @paomorejon: 📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Ig…
📌Shock Cardiogénico: Takotsubo (TC) vs IAM (observacional) 🔖TC-SC •1.2% vs 5-12% •📈disfunción del VI •📉FMO •📉mortalidad •Igual uso de MCS ⚠️No todo shock es lo mismo: Existen fenotipos 💪🏻Debemos entenderlo By @SarasVallabhMD https://t.co/oGBgBHNGYp http
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @ShashankSinhaMD: Congrats, Saras! Honored to contribute to editorial w/ @behnam_tehrani & @cmrosner "Not All Shock is Created Equal" ht…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @ShashankSinhaMD: Congrats, Saras! Honored to contribute to editorial w/ @behnam_tehrani & @cmrosner "Not All Shock is Created Equal" ht…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
Strong work @SarasVallabhMD Congratulations!
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @ShashankSinhaMD: Congrats, Saras! Honored to contribute to editorial w/ @behnam_tehrani & @cmrosner "Not All Shock is Created Equal" ht…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @SarasVallabhMD: Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy a…
RT @ShashankSinhaMD: Congrats, Saras! Honored to contribute to editorial w/ @behnam_tehrani & @cmrosner "Not All Shock is Created Equal" ht…
RT @ShashankSinhaMD: Congrats, Saras! Honored to contribute to editorial w/ @behnam_tehrani & @cmrosner "Not All Shock is Created Equal" ht…
Congrats, Saras! Honored to contribute to editorial w/ @behnam_tehrani & @cmrosner "Not All Shock is Created Equal" https://t.co/Zvtq9HTX9E @inovaheart @InovaHealth @coconnormd @mfiuzat @ZeroPatientHarm @mpsotka @DoctorRTC @_lbcooper #cardiogenicshock
Published today in @JACCJournals our study on the largest cohort of #CardiogenicShock due to #TakotsuboCardiomyopathy and how it compares to #AMI - https://t.co/ZmZ1svf7dG. Congratulations to @MayoClinicCV team! Thank you @behnam_tehrani @ShashankSinhaMD f